EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity

Paulien Baeten, Karen Beets, Tessa Schalley, Janne Verreycken, Gayel Duran, Daphne Lintsen, Lisa Schuetz, Xue Zhong, Rinke Nieuwschepen, Melissa Schepers, Brecht Moonen, Jeroen Bogie und 19 weitere

Advanced Science · 2026

DOI: 10.1002/advs.76382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Paulien Baeten und 30 weiteren Autor:innen. Beteiligte Einrichtung: University MS Center, Campus Diepenbeek, Diepenbeek, Belgium. Hauptthemen laut MEDLINE: Autoantigens, RNA, Messenger, Encephalomyelitis, Autoimmune, Experimental, Autoimmunity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VLAIO, Barbara D. Cammett Breakthrough T1D Center of Excellence in New England of the Breakthrough T1D Foundation, Agentschap Innoveren en Ondernemen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune diseases like multiple sclerosis (MS) and type 1 diabetes (T1D) lack therapies that induce durable, antigen‐specific immune tolerance. We investigated whether mRNA lipid nanoparticles (LNPs) encoding disease‐relevant autoantigens could re‐establish immune homeostasis in preclinical models. While mRNA‐LNP microbial vaccines evoke strong effector immune responses, we show that both systemic and intramuscular delivery of MOG 27‐63 mRNA‐loaded LNPs attenuated disease severity in experimental autoimmune encephalomyelitis (EAE). Antigen‐specific protection was similarly observed in a T1D adoptive transfer model. Therapeutic efficacy achieved using immunostimulatory LNPs challenges the current assumption that tolerogenic mRNA vaccines require immune‐silent LNPs. Furthermore, divergent outcomes between autoantigens and irrelevant antigens suggest that antigen identity determines whether mRNA‐LNPs promote immune tolerance or activation. Mechanistically, optimized LNPs efficiently targeted antigen‐presenting cells (APCs) in the liver and spleen. This promoted a homeostatic APC phenotype and a hyporesponsive CD4 + T cell phenotype without inducing regulatory T cells (Tregs). Therefore, autoantigen mRNA was co‐delivered with “immunoregulatory” mRNAs encoding cytokines (IL‐2 mutein) or chemokines (CCL1) known to enhance Treg expansion and recruitment. This co‐delivery further improved clinical outcomes in EAE. Together, these findings demonstrate that systemic and intramuscular treatment with mRNA‐LNPs encoding autoantigens alongside immunoregulatory molecules represents a promising strategy for antigen‐specific immunotherapy in autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantigensRNA, MessengerEncephalomyelitis, Autoimmune, ExperimentalAutoimmunityNanoparticlesVaccinationAnimalsMiceFemaleDisease Models, AnimalImmune ToleranceMice, Inbred C57BLLipidsNanovaccinesLiposomes

Stichwörter der Autor:innen

autoimmune diseaseslipid nanoparticlesmRNA therapeuticstolerizing vaccines

Substanzen

AutoantigensRNA, MessengerLipid NanoparticlesLipidsNanovaccinesLiposomes

Autor:innen und Institutionen

  • University MS Center, Campus Diepenbeek, Diepenbeek, Belgium.
  • Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium.
  • etherna immunotherapies NV, Niel, Belgium.
  • Internal Medicine, Maastricht University, Maastricht, Netherlands.
  • Department of Neuroscience, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium.
  • Department of Psychiatry and Neuropsychology, Mental Health and Neuroscience Research Institute, Maastricht University, Maastricht, Netherlands.

ORCID-Profile: Bieke Broux

Förderung

  • VLAIO
  • Barbara D. Cammett Breakthrough T1D Center of Excellence in New England of the Breakthrough T1D Foundation
  • Agentschap Innoveren en Ondernemen

Zitieren

APA

Baeten, P., Beets, K., Schalley, T., Verreycken, J., Duran, G., Lintsen, D., Schuetz, L., Zhong, X., Nieuwschepen, R., Schepers, M., Moonen, B., Bogie, J., Van Broeckhoven, J., Heirman, C., Van den Heuvel, J., Vanderborght, B., Varela, I., Nouille, R., Jacobs, L., …, & Broux, B. (2026). Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity. Advanced Science. https://doi.org/10.1002/advs.76382

Vancouver

Baeten P, Beets K, Schalley T, Verreycken J, Duran G, Lintsen D, et al. Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity. Advanced Science. 2026. doi:10.1002/advs.76382

BibTeX
@article{Baeten2026,
  author = {Baeten, Paulien and Beets, Karen and Schalley, Tessa and Verreycken, Janne and Duran, Gayel and Lintsen, Daphne and Schuetz, Lisa and Zhong, Xue and Nieuwschepen, Rinke and Schepers, Melissa and Moonen, Brecht and Bogie, Jeroen and Van Broeckhoven, Jana and Heirman, Carlo and Van den Heuvel, Jurgen and Vanderborght, Bart and Varela, Ismael and Nouille, Roxanne and Jacobs, Lotte and Filtjens, Jessica and Kasmi, Sabah and Seynaeve, Elise and Mavrovouna, Veronica and De Vrieze, Jana and Brehm, Michael A and Maréchal, Sandra and Janssens, Sophie and Lambolez, Florence and Hellings, Niels and De Koker, Stefaan and Broux, Bieke},
  title = {Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.76382}
}
Kostenlos starten →